Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence

被引:23
作者
Brody, Jonathan R. [2 ,3 ]
Hucl, Tomas [1 ]
Costantino, Christina L. [2 ]
Eshleman, James R. [1 ]
Gallmeier, Eike [1 ]
Zhu, Heng [1 ]
van der Heijden, Michiel S. [1 ]
Winter, Jordan M. [2 ]
Wikiewicz, Agnieszka K. [3 ]
Yeo, Charles J. [2 ]
Kern, Scott E. [1 ]
机构
[1] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA
[2] Thomas Jefferson Univ, Jefferson Pancreas Biliary & Related Canc Ctr, Dept Surg, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Jefferson Pancreas Biliary & Related Canc Ctr, Dept Pathol, Philadelphia, PA 19107 USA
关键词
COLON-CARCINOMA-CELLS; DIHYDROPYRIMIDINE DEHYDROGENASE; COLORECTAL-CANCER; 5-FLUOROURACIL CYTOTOXICITY; IMMUNOLOGICAL QUANTITATION; SACCHAROMYCES-CEREVISIAE; FLUORINATED PYRIMIDINES; THYMIDINE PHOSPHORYLASE; ADJUVANT CHEMOTHERAPY; EXPRESSION LEVELS;
D O I
10.1158/0008-5472.CAN-08-3610
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The major determinants of 5-flurouracil (5-FU) response would seem, based on accumulated literature, to be thymidylate synthase (TYMS, TS) expression levels, TS gene modifications, and TP53 status. We tested 5-FU sensitivity in yeast and human cancer cell models in which TS or TP53 alleles and expression were varied. Polymorphic TS tandem repeat status, TS expression levels reported, TS intragenic mutations, and TP53 status in outbred and experimental cancer cell lines did not predict 5-FU sensitivity or resistance. Novel observations included a dose-resistant persistence of unbound TS protein in many cancers and, upon 5-FU treatment of the colon cancer cell line, HCT116, evidence of allelic switching favoring transcripts of the mutant TS allele. The reported alleles having an intragenic mutation could not be causally associated with major degrees of 5-FU sensitivity. In yeast, TS protein was altered upon treatment with HUMP, but 5-FU toxicity seemed to be largely RNA-based, being rescued by uridine rather than by thymidine. Cancer cell lines were also rescued from 5-FU toxicity with uridine rather than thymidine. Additionally, a TS (CDC21) knockout yeast strain, obviating any potential role for TS protein as a target, was hypersensitive to 5-FU. When denatured proteins from cancer cells treated with radiolabeled 5-FU were labeled, species with alternative molecular weights other than TS were visualized, providing further evidence for alternative 5-FU protein targets. These data emphasize that TS and TP53 status do not consistently explain the variance in responses of fluoropyrimidine-treated cancer cells, in part due to RNA-based toxicity. [Cancer Res 2009;69(3):984-91]
引用
收藏
页码:984 / 991
页数:8
相关论文
共 50 条
[1]   c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis [J].
Arango, D ;
Mariadason, JM ;
Wilson, AJ ;
Yang, W ;
Corner, GA ;
Nicholas, C ;
Aranes, MJ ;
Augenlicht, LH .
BRITISH JOURNAL OF CANCER, 2003, 89 (09) :1757-1765
[2]  
Arango D, 2001, CANCER RES, V61, P4910
[3]  
Augenlicht LH, 1997, CANCER RES, V57, P1769
[4]   Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer:: A model for patient classification to aid fluoropyrimidine therapy [J].
Brody, Jonathan R. ;
Hucl, Tomas ;
Gallmeier, Eike ;
Winter, Jordan M. ;
Kern, Scott E. ;
Murphy, Kathleen M. .
CANCER RESEARCH, 2006, 66 (19) :9369-9373
[5]   A proposed clinical test for monitoring fluoropyrimidine therapy - Detection and stability of thymidylate synthase ternary complexes [J].
Brody, Jonathan R. ;
Gallmeier, Eike ;
Yoshimura, Kiyoshi ;
Hucl, Tomas ;
Kulesza, Peter ;
Canto, Marcia I. ;
Hruban, Ralph H. ;
Schulick, Richard D. ;
Kern, Scott E. .
CANCER BIOLOGY & THERAPY, 2006, 5 (08) :923-927
[6]   Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media [J].
Brody, JR ;
Calhoun, ES ;
Gallmeier, E ;
Creavalle, TD ;
Kern, SE .
BIOTECHNIQUES, 2004, 37 (04) :598-+
[7]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[8]  
CORY JG, 1979, CANCER RES, V39, P4905
[9]   IMMUNOLOGICAL QUANTITATION OF THYMIDYLATE SYNTHASE FDUMP-5,10-METHYLENETETRAHYDROFOLATE TERNARY COMPLEX WITH THE MONOCLONAL-ANTIBODY TS-106 [J].
DRAKE, JC ;
ALLEGRA, CJ ;
JOHNSON, PG .
ANTI-CANCER DRUGS, 1993, 4 (04) :431-435
[10]  
DREWINKO B, 1980, CANCER-AM CANCER SOC, V45, P1144, DOI 10.1002/1097-0142(19800315)45:5+<1144::AID-CNCR2820451319>3.0.CO